

Figure S1. Detection of the cell migration and invasion abilities of cisplatin- and carboplatin-resistant cells and sensitive ovarian cancer cells as detected by the Transwell migration and invasion methods. (A) Migration and invasion results between sensitive ovarian cancer cells SKOV3, HeyA8, A2780 and resistant SKOV3-CDDP, HeyA8-CDDP, A2780-CBP cell lines. (B) Quantification of the percentage of migration is shown between the parental sensitive/resistant: (a) SKOV3/SKOV3-CDDP, (b) HeyA8/HeyA8-CDDP and (c) A2780/A2780-CBP cell lines. (C) Quantification of the percentage of invasion is shown between the parental sensitive/resistant: (a) SKOV3/SKOV3-CDDP, (b) HeyA8/HeyA8-CDDP and (c) A2780/A2780-CBP cell lines. **P<0.01, compared with the sensitive parental cell line. CDDP, cisplatin; CBP, carboplatin.




Table SI. Case demographics of GSE41499 and GSE33482.

Characteristics	GSE114206		GSE41499	
	Sensitive	Resistant	Sensitive	Resistant
Patients (n)	6	6	1	1
Age, years				
Median	63	62	74	74
Pathological type				
HGSC	6	6	1	1
Grade 3	6	6	1	1
NACT+IDS	1	4	0	0
Primary surgery	5	2	1	1
Post-chemotherapy	6	6	1	1
Stage				
IIIc-IV	6	6	1	1
Debulking status				
No residual disease	6	6	1	1
Optimal debulking	0	0	0	0
Suboptimal debulking	0	0	0	0
Progression-free survival (months)	28	3.5	11.2	11.2

NACT, neoadjuvant chemotherapy; HGSC, high-grade serous ovarian cancer; IDS, interval debulking surgery.

Table SII. Demographics of the cases in GSE109934 (N=19).

Characteristics	Patient data
Age in years, median (range)	74 (53-85)
BMI in kg/m ² , median (range)	25.8 (18.6-31.7)
Pathological type	
HGSC	19
Stage	
IIIc-IV	19
NACT cycles, median (range)	3 (2-6)
IDS	19
Debulking status	
No residual disease	7
Optimal debulking	10
Suboptimal debulking	2
Platinum status	
Resistant	9
Sensitive	10
Status after adjuvant therapy	
Persistence	5
Complete response	12
Unknown	2
CA-125	
Pre-NACT (kU/l), median (range)	540.0 (33.33-13818.0)
Post-NACT (kU/l), median (range)	37.9 (4.7-2803.0)
Mean follow-up time (months), median (range)	28.93 (5.80-32.33)
Progression-free survival (months), median (range)	17.13 (8.03-26.10)
Overall survival (months), median (range)	27.30 (4.33-44.03)
NACT, neoadjuvant chemotherapy; HGSC, high-grade serous ovarian cancer; IDS, interval debulking surgery; CA-125, cancer antigen 125.	